Open access
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia
Aziz Farhat
Georgina El Hajjar
H. Kantarjian
Koiji Sasaki
N. Short
Branko Cuglievan
S. Loghavi
K. Patel
A. Bataller
Wei-Ying Jen
M. Yilmaz
G. Montalban-Bravo
D. Hammond
N. Pemmaraju
Naval G. Daver
F. Ravandi
Elias J. Jabbour
T. Kadia
G. Borthakur
G. Garcia-Manero
Courtney D. DiNardo
G. Issa
Medicine
Abstract
Nucleophosmin 1‐mutated (NPM1mt) acute myeloid leukemia (AML) is associated with a relatively favorable prognosis though long‐term outcomes remain suboptimal without clear predictors identified by therapy.